A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma

Exclusion Criteria

• •1. Have previously received systemic or local treatment including chemotherapy;
• •2. Previously received autologous stem cell transplantation;
• •3. Previous history of other malignant tumors, except skin basal cell carcinoma and cervical carcinoma in situ;
• •4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases and serious infectious diseases;
• •5. Lymphoma involves the central nervous system;
• •6. Primary mediastinal large B-cell lymphoma;
• •7. Left ventricular ejection fraction \< 50%;
• •8. Laboratory test values at the time of screening: (unless due to lymphoma);
• •1. Neutrophils \< 1.5 x 109/L;
• •2. Platelet \< 75 x 109/L;
• •3. ALT or AST were 2 times higher than the upper limit of normal, AKP and bilirubin were 1.5 times higher than the upper limit of normal;
• •4. creatinine levels higher than 1.5 times the upper limit of normal;
• •9. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
• •10. Pregnant or lactating women;
• •12. Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study.